id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0940-0007,FDA,FDA-2014-E-0940,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-23T05:00:00Z,2018,11,2018-11-23T05:00:00Z,,2018-11-23T16:06:32Z,,0,0,09000064838f607c
FDA-2014-E-0940-0006,FDA,FDA-2014-E-0940,"Determination of Regulatory Review Period for Purposes of Patent
Extension; LYMPHOSEEK",Notice,Determinations,2018-02-22T05:00:00Z,2018,2,2018-02-22T05:00:00Z,2018-04-24T03:59:59Z,2018-02-22T18:45:39Z,2018-03610,0,0,0900006482f51fe0
FDA-2014-E-0940-0005,FDA,FDA-2014-E-0940,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T15:57:40Z,,0,0,09000064826a1e18
FDA-2014-E-0940-0004,FDA,FDA-2014-E-0940,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T16:23:22Z,,0,0,0900006482434339
FDA-2014-E-0940-0003,FDA,FDA-2014-E-0940,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-05T05:00:00Z,2015,11,2015-11-05T05:00:00Z,,2015-11-05T14:55:27Z,,0,0,0900006481d1445d
FDA-2014-E-0940-0002,FDA,FDA-2014-E-0940,"Patent Extension Application from Porter Wright Miller & Arthus LLP  (Navidea Biopharmaceuticals, Inc.)",Other,Application,2014-07-07T04:00:00Z,2014,7,2014-07-07T04:00:00Z,,2014-07-07T16:59:30Z,,0,0,0900006481793f8e
FDA-2014-E-0940-0001,FDA,FDA-2014-E-0940,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2014-07-07T04:00:00Z,2014,7,2014-07-07T04:00:00Z,,2014-07-07T16:57:29Z,,0,0,0900006481793cf6